A Phase 1-2, XIAP Antisense AEG35156 With Weekly Paclitaxel in Patients With Advanced Breast Cancer
Status:
Terminated
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This is an open-label multicenter, phase 1-2 study. Following determination of the
recommended AEG35156 dose in combination with weekly paclitaxel in the initial Phase 1 part
of this study, additional patients will be enrolled in the Phase 2 part of the study to
assess the activity of the combination in advanced breast cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Aegera Therapeutics
Treatments:
Albumin-Bound Paclitaxel Paclitaxel X-Linked Inhibitor of Apoptosis Protein